Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT‐Epistaxis

Epistaxis is the most frequent clinical manifestation of hereditary hemorrhagic telangiectasia (HHT). Several topical, systemic, and surgical treatments have been tried, but none have been completely effective. The aim of the present study is to evaluate whether a combined treatment sclerotherapy and topical therapy with propranolol 0.5% nasal formulation would reduce the epistaxis due to HHT and improve patient's quality of life.

• Publication year

  2019

• Venue

  The Laryngoscope

• Publication date

  2019-03-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/lary.27930PMID 30908653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence‐based review

  2018cited by this paper
• Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)

  2017influential reference
• Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study

  2017cited by this paper
• Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients

  2017cited by this paper
• Infantile haemangioma.

  2017cited by this paper
• Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report

  2017cited by this paper
• Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia

  2016cited by this paper
• The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia

  2016cited by this paper
• Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.

  2016influential reference
• Natural History of Epistaxis in a Spanish Population with Hereditary Haemorrhagic Telangiectasia ( HHT )

  2016cited by this paper
• Evaluation of β-blocker gel and effect of dosing volume for topical delivery.

  2015cited by this paper
• Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia

  2015cited by this paper
• Propranolol induces regression of hemangioma cells via the down‐regulation of the PI3K/Akt/eNOS/VEGF pathway

  2015cited by this paper
• Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia

  2014cited by this paper
• The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey

  2014cited by this paper
• Optimal management of hereditary hemorrhagic telangiectasia

  2014cited by this paper
• First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT)

  2014cited by this paper
• Evaluation of Skin Permeation of β-Blockers for Topical Drug Delivery

  2013cited by this paper
• Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.

  2013cited by this paper
• Efficacy of a topical sesame/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis

  2013cited by this paper
• Lifestyle and Dietary Influences on Nosebleed Severity in Hereditary Hemorrhagic Telangiectasia

  2013cited by this paper
• Evaluation of Skin Permeation of β-Blockers for Topical Drug Delivery

  2012cited by this paper
• Bevacizumab in hereditary hemorrhagic telangiectasia‐associated epistaxis: Effectiveness of an injection protocol based on the vascular anatomy of the nose

  2012cited by this paper
• A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia

  2012cited by this paper
• Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia

  2012influential reference
• Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy

  2012cited by this paper
• Local sclerotherapy with polydocanol (Aethoxysklerol®) for the treatment of Epistaxis in Rendu-Osler-Weber or Hereditary Hemorrhagic Telangiectasia (HHT): 15 years of experience.

  2012cited by this paper
• Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia

  2012influential reference
• Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia‐associated epistaxis

  2011cited by this paper
• Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.

  2011cited by this paper
• An epistaxis severity score for hereditary hemorrhagic telangiectasia

  2010cited by this paper
• Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells.

  2010cited by this paper
• International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia

  2009cited by this paper
• The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study.

  2009cited by this paper
• Antiestrogen therapy for hereditary hemorrhagic telangiectasia: A double‐blind placebo‐controlled clinical trial

  2009cited by this paper
• [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid].

  2007cited by this paper
• Tratamiento de las epistaxis en la telangiectasia hemorrágica hereditaria (enfermedad de Rendu-Osler-Weber) con ácido tranexámico

  2007cited by this paper
• Plasma Surgery and Topical Estriol: Effects on the Nasal Mucosa and Long-Term Results in Patients with Osier's Disease

  2003cited by this paper
• [EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care].

  2001cited by this paper
• El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria

  2001cited by this paper
• Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

  2000cited by this paper
• Telangiectasia hemorrágica hereditaria o enfermedad de Rendu Osler Weber

  1994cited by this paper

• Propranolol Reduces Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Large Retrospective Study

  2026cites this paper
• Consensus on Sclerotherapy for Patients With Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.

  2025cites this paper
• Non-HHT Arteriovenous Malformation Epistaxis: Successful Embolization in Young Patient—Case Report

  2024cites this paper
• Health-Related Quality of Life Outcome Measures in Individuals With Hereditary Hemorrhagic Telangiectasia: A Scoping Review

  2023cites this paper
• Sclerotherapy for Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review

  2022cites this paper
• Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management

  2022cites this paper
• The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases

  2022cites this paper
• Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds

  2021cites this paper
• Long-term efficacy assessment of current treatment options for epistaxis in HHT

  2021cites this paper
• Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience

  2021cites this paper
• SARS-CoV-2 Infection in Hereditary Hemorrhagic Telangiectasia Patients Suggests Less Clinical Impact Than in the General Population

  2021cites this paper
• Pathogenesis and therapy of arteriovenous malformations: A case report and narrative review

  2021cites this paper
• Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial

  2020cites this paper
• Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.

  2020cites this paper
• Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding

  2020cites this paper
• Update June 2019

  2019cites this paper
• HHT: Kombinationstherapie stoppt Nasenbluten

  2019cites this paper